Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.
Evdoshenko E, Stepanova A, Shumilina M, Davydovskaya M, Khachanova N, Neofidov N, Kalinin I, Popova E, Dubchenko E, Pozhidaeva N, Volkov A, Sivertseva S, Prilenskaya A, Malkova N, Korobko D, Vergunova I, Shchur S, Makshakov G.
Evdoshenko E, et al. Among authors: khachanova n.
PLoS One. 2019 May 28;14(5):e0217303. doi: 10.1371/journal.pone.0217303. eCollection 2019.
PLoS One. 2019.
PMID: 31136608
Free PMC article.